Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2024	Mar. 31, 2023
Deferred Royalty Obligation [Line Items]
Non-cash interest expense on deferred royalty obligation		$ 7,184	$ 0
Percentage of interest rate amortize liability		19.00%
Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Blackstone Life Sciences | Maximum
Deferred Royalty Obligation [Line Items]
Milestone payment receivable	250,000
2015 License Agreement | Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Transaction costs incurred	3,800
2015 License Agreement | Blackstone Life Sciences | Royalty
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Revenue interest percentage	4.00%	4.00%
Amendment 3 2015 License Agreement | Vaxcyte | Royalty
Deferred Royalty Obligation [Line Items]
Revenue interest percentage		4.00%